KalVista announces publication of first oral factor XIIa data

KalVista Pharmaceuticals announced that data from the first report of an oral, potent, and selective FXIIa inhibitor has been published in the peer-reviewed scientific journal, Frontiers in Pharmacology. The article describes the pharmacology of a representative compound from KalVista’s portfolio of structurally diverse, oral Factor XII inhibitors, including: Potent, selective inhibition of both FXII zymogen and FXIIa, thereby suppressing both the initiation and amplification of kallikrein-kinin system activation; Blockage of KKS-mediated edema in preclinical HAE models in vivo. “The publication is the first report of a potent and specific FXIIa inhibitor with high oral availability in multiple species and demonstrated efficacy in HAE models in vivo,” said Andrew Crockett, CEO of KalVista. “This once again demonstrates our scientific leadership in medicinal chemistry and KKS biology. It also provides new insight on the inhibition of FXII zymogen.”